Cargando…
Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
PURPOSE: Postmastectomy radiation therapy (PMRT) in T1–T2 tumors with 1–3 positive axillary lymph nodes (ALNs) is controversial. This study was to identify prognostic factors of locoregional control (LRC) following mastectomy with or without PMRT for patients with T1-2N1 breast cancer and to discuss...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558198/ https://www.ncbi.nlm.nih.gov/pubmed/34490502 http://dx.doi.org/10.1007/s10549-021-06378-2 |
_version_ | 1784592502819389440 |
---|---|
author | Wang, Xiaofang Zhang, Li Zhang, Xiaomeng Luo, Jurui Wang, Xuanyi Chen, Xingxing Yang, Zhaozhi Mei, Xin Yu, Xiaoli Zhang, Zhen Guo, Xiaomao Shao, Zhimin Ma, Jinli |
author_facet | Wang, Xiaofang Zhang, Li Zhang, Xiaomeng Luo, Jurui Wang, Xuanyi Chen, Xingxing Yang, Zhaozhi Mei, Xin Yu, Xiaoli Zhang, Zhen Guo, Xiaomao Shao, Zhimin Ma, Jinli |
author_sort | Wang, Xiaofang |
collection | PubMed |
description | PURPOSE: Postmastectomy radiation therapy (PMRT) in T1–T2 tumors with 1–3 positive axillary lymph nodes (ALNs) is controversial. This study was to identify prognostic factors of locoregional control (LRC) following mastectomy with or without PMRT for patients with T1-2N1 breast cancer and to discuss the selection of patients who might omit PMRT. MATERIALS AND METHODS: Between January 2006 and December 2012, the data of 1474 postmastectomy patients staged pT1-2N1 were analyzed. PMRT was applied in 663 patients. LRC and disease-free survival (DFS) were calculated using the Kaplan–Meier method. Cox regression model was applied in the univariate and multivariate analyses to recognize the recurrence risk factors. RESULTS: With the median follow-up duration of 93 months (range, 5–168 months), 78 patients (5.3%) failed to secure LRC and 220 patients (14.9%) experienced any recurrence. The 7.7-year LRC and DFS was 94.9% and 85.4% respectively in the entire cohort. PMRT significantly improved 7.7-year LRC from 93.4% to 96.6% (p = 0.005), but not the DFS (p = 0.335). Multivariate analysis revealed that PMRT was an independent prognostic factor of LRC (p < 0.001), meanwhile, age ≤ 40 years (p = 0.012), histological grade 3 (p = 0.004), 2–3 positive nodes (p < 0.001) and tumor size of 3–5 cm (p = 0.045) were significantly associated with decreased LRC. The 7.7-year LRC for patients with 0, 1, and 2–4 risk factors was 97.7% / 98.9% (p = 0.233), 95.3% / 98.0% (p = 0.092), and 80.3% / 94.8% (p < 0.001) in the non-PMRT and PMRT group, respectively. CONCLUSIONS: In patients with T1-2N1 breast cancer, clinical-pathological factors including young age, histological grade 3, 2–3 positive nodes, and tumor size of 3–5 cm were identified to be predictors of a poorer LRC following mastectomy. Patients with 0–1 risk factor might consider the omission of PMRT. |
format | Online Article Text |
id | pubmed-8558198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-85581982021-11-15 Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? Wang, Xiaofang Zhang, Li Zhang, Xiaomeng Luo, Jurui Wang, Xuanyi Chen, Xingxing Yang, Zhaozhi Mei, Xin Yu, Xiaoli Zhang, Zhen Guo, Xiaomao Shao, Zhimin Ma, Jinli Breast Cancer Res Treat Clinical Trial PURPOSE: Postmastectomy radiation therapy (PMRT) in T1–T2 tumors with 1–3 positive axillary lymph nodes (ALNs) is controversial. This study was to identify prognostic factors of locoregional control (LRC) following mastectomy with or without PMRT for patients with T1-2N1 breast cancer and to discuss the selection of patients who might omit PMRT. MATERIALS AND METHODS: Between January 2006 and December 2012, the data of 1474 postmastectomy patients staged pT1-2N1 were analyzed. PMRT was applied in 663 patients. LRC and disease-free survival (DFS) were calculated using the Kaplan–Meier method. Cox regression model was applied in the univariate and multivariate analyses to recognize the recurrence risk factors. RESULTS: With the median follow-up duration of 93 months (range, 5–168 months), 78 patients (5.3%) failed to secure LRC and 220 patients (14.9%) experienced any recurrence. The 7.7-year LRC and DFS was 94.9% and 85.4% respectively in the entire cohort. PMRT significantly improved 7.7-year LRC from 93.4% to 96.6% (p = 0.005), but not the DFS (p = 0.335). Multivariate analysis revealed that PMRT was an independent prognostic factor of LRC (p < 0.001), meanwhile, age ≤ 40 years (p = 0.012), histological grade 3 (p = 0.004), 2–3 positive nodes (p < 0.001) and tumor size of 3–5 cm (p = 0.045) were significantly associated with decreased LRC. The 7.7-year LRC for patients with 0, 1, and 2–4 risk factors was 97.7% / 98.9% (p = 0.233), 95.3% / 98.0% (p = 0.092), and 80.3% / 94.8% (p < 0.001) in the non-PMRT and PMRT group, respectively. CONCLUSIONS: In patients with T1-2N1 breast cancer, clinical-pathological factors including young age, histological grade 3, 2–3 positive nodes, and tumor size of 3–5 cm were identified to be predictors of a poorer LRC following mastectomy. Patients with 0–1 risk factor might consider the omission of PMRT. Springer US 2021-09-06 2021 /pmc/articles/PMC8558198/ /pubmed/34490502 http://dx.doi.org/10.1007/s10549-021-06378-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Trial Wang, Xiaofang Zhang, Li Zhang, Xiaomeng Luo, Jurui Wang, Xuanyi Chen, Xingxing Yang, Zhaozhi Mei, Xin Yu, Xiaoli Zhang, Zhen Guo, Xiaomao Shao, Zhimin Ma, Jinli Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? |
title | Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? |
title_full | Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? |
title_fullStr | Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? |
title_full_unstemmed | Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? |
title_short | Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? |
title_sort | impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with t1-2n1 breast cancer: who can omit adjuvant radiotherapy? |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558198/ https://www.ncbi.nlm.nih.gov/pubmed/34490502 http://dx.doi.org/10.1007/s10549-021-06378-2 |
work_keys_str_mv | AT wangxiaofang impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT zhangli impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT zhangxiaomeng impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT luojurui impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT wangxuanyi impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT chenxingxing impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT yangzhaozhi impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT meixin impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT yuxiaoli impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT zhangzhen impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT guoxiaomao impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT shaozhimin impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy AT majinli impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy |